Drug Profile
VX 985
Alternative Names: VX-985Latest Information Update: 18 Aug 2014
Price :
$50
*
At a glance
- Originator Vertex Pharmaceuticals
- Class Antivirals
- Mechanism of Action Hepatitis C protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 01 May 2014 Discontinued - Phase-I for Hepatitis C in USA (PO)
- 22 Oct 2010 Vertex Pharmaceuticals completes enrolment in its Phase-I trial [NCT01144936] for Hepatitis C in USA
- 06 Jul 2010 Phase-I clinical trials in Hepatitis C in USA (PO)